Drug Trial Radar · NCT06443489
A Trial of SHR-4849 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 26, 2024
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection in Advanced Solid Tumors. To explore the reasonable dosage of SHR-4849 for Advanced Solid Tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-4849Drug
SHR-4849
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT:the incidence of events associated with the investigational drug determined by the investigator during the observation periodTime frame: up to 21 days
- Incidence and severity of AE/SAE:According to NCI-CTCAE v5.0 evaluation criteria, from the signing of informed consent to the end of safety follow-up;Time frame: up to 24 months
- MTD or MAD:after all subjects of dose escalation phase be enrolled,and all subjects complete at least one cycle of dosing observation.Time frame: up to 24 months
- RP2D:after all subjects of dose escalation and dose expansion phase be enrolled,and all subjects complete at least one cycle of dosing observation.Time frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jilin Cancer Hospital
Jilin City, Changchun, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.